1. Home
  2. HRMY vs RUN Comparison

HRMY vs RUN Comparison

Compare HRMY & RUN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Harmony Biosciences Holdings Inc.

HRMY

Harmony Biosciences Holdings Inc.

N/A

Current Price

$36.75

Market Cap

2.2B

Sector

Health Care

ML Signal

N/A

Logo Sunrun Inc.

RUN

Sunrun Inc.

N/A

Current Price

$8.88

Market Cap

2.1B

Sector

Miscellaneous

ML Signal

N/A

Company Overview

Basic Information
Metric
HRMY
RUN
Founded
2017
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Industrial Machinery/Components
Sector
Health Care
Miscellaneous
Exchange
Nasdaq
Nasdaq
Market Cap
2.2B
2.1B
IPO Year
2020
2015

Fundamental Metrics

Financial Performance
Metric
HRMY
RUN
Price
$36.75
$8.88
Analyst Decision
Buy
Buy
Analyst Count
12
19
Target Price
★ $48.08
$14.21
AVG Volume (30 Days)
993.4K
★ 8.5M
Earning Date
11-04-2026
11-04-2026
Dividend Yield
N/A
N/A
EPS Growth
7.97
★ 113.35
EPS
★ 1.84
1.04
Revenue
★ $868,453,000.00
$858,578,000.00
Revenue This Year
$18.17
$4.94
Revenue Next Year
$13.71
$3.38
P/E Ratio
$20.01
★ $8.37
Revenue Growth
★ 21.51
12.97
52 Week Low
$25.90
$6.78
52 Week High
$43.49
$21.95

Technical Indicators

Market Signals
Indicator
HRMY
RUN
Relative Strength Index (RSI) 50.13 62.12
Support Level $36.74 $8.34
Resistance Level $39.40 $9.17
Average True Range (ATR) 1.50 0.46
MACD 0.17 0.16
Stochastic Oscillator 80.36 99.62

Price Performance

Historical Comparison
HRMY
RUN

About HRMY Harmony Biosciences Holdings Inc.

Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company has one reportable segment: rare neurological diseases. Its product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.

About RUN Sunrun Inc.

Sunrun is engaged in the design, development, installation, sale, ownership, and maintenance of residential solar energy systems in the United States. The company acquires customers directly and through relationships with various solar and strategic partners. The solar systems are constructed by Sunrun or by Sunrun's partners and are owned by the company. Sunrun's customers typically enter into 20- to 25-year agreements to utilize its solar energy system. The company also sells solar energy systems and products, such as panels and racking, and solar leads generated to customers.

Share on Social Networks: